Objective: Unlike complete (R0) resection guidelines, current National Comprehensive Cancer Network (NCCN) adjuvant therapy guidelines after incomplete (R1/R2) resection of nonesmall cell lung cancer (NSCLC) are based on low-level evidence. We attempted to validate them.
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Lung cancer accounts for approximately 27% of all annual US cancer deaths. 1 Most long-term survivors are among the 29% of patients who have undergone curative-intent surgical resection. 2, 3 In high-risk patients, adjuvant chemotherapy [4] [5] [6] and/or postoperative radiotherapy (PORT) may improve survival. 7 The quality of evidence for the benefit of these treatments varies by stage and margin status. Randomized clinical trials (RCTs) and a pooled analysis have demonstrated the benefit of adjuvant chemotherapy in completely (R0) resected patients with T-category 2b or more advanced primary tumors, and those with nodal metastasis. [4] [5] [6] 11 A large meta-analysis showed the harmfulness of PORT in R0-resected patients without mediastinal nodal metastasis 12, 13 ; a retrospective analysis of the US Surveillance, Epidemiology and End Results database and an unplanned retrospective analysis of a clinical trial suggest R0 patients with mediastinal nodal metastasis may benefit from PORT. 7, 10 Unlike the situation after complete resection, there is no RCT evidence to guide adjuvant management for the 2% to 17% of nonesmall cell lung cancer (NSCLC) resections with microscopic (R1)-or macroscopic (R2)-positive margins. [14] [15] [16] However, recipients of incomplete resection are at significantly high risk for early death, irrespective of stage. [16] [17] [18] Current National Comprehensive Cancer Network (NCCN) guideline recommendations for postoperative management of these patients are based on unverified expert opinion. 19 Therefore, the guidelines need validation.
We evaluated the survival impact of 4 different adjuvant therapy options, after incomplete resection, in the National Cancer Database (NCDB) to determine which options seemed best for patients grouped into stage clusters as in the NCCN guidelines. 19 
METHODS

Cohort Selection
We used the NCDB, an oncology database sourced from Commission on Cancer-accredited Facilities, which covers approximately 70% of newly diagnosed US cancer cases. 20, 21 We selected patients with surgically resected pathologic stage I-IIIA NSCLC from 2004 to 2011 (International Classification of Disease for Oncology, 3rd version site codes C34.0-C34.9), excluding patients with missing information on last date of contact, administration (or date of administration) of radiation or chemotherapy, facility, or patient location. We also excluded patients with more than 1 surgical procedure, neoadjuvant radiation or chemotherapy, no (or unknown) nodal examination, adjuvant therapy more than 180 days past date of surgery, government insurance, and death within 60 days of surgery.
Objectives
The primary objective of this analysis was to compare stage-specific survival between postoperative therapy modalities in patients with incomplete surgical resection (R1/R2) who did not undergo re-resection. We used a parallel analysis of R0 patients to evaluate whether our data and methodology produced results congruent with existing high-level evidence for treatment of R0 patients.
Adjuvant Therapy Options
We classified postoperative therapy modalities as chemotherapy, radiotherapy, chemoradiation, or no treatment. Therapy administered within 6 months after surgery, at any dose level, was included as postoperative therapy. The median time from surgery to onset of treatment, by modality, is reported in Table E1 . For combined-modality chemoradiation therapy, the second modality had to begin within 2 months of the end of the first. The time from surgery to initiation of adjuvant therapy was evaluated to verify that adjuvant modalities were not typically used for the purpose of salvage therapy in this cohort.
NCCN Stage Groups and Adjuvant Therapy Guidelines
NCCN recommendations for adjuvant therapy are based on pathologic stage, categorized into the following 4 groups: (1) stage IA (T1ab, N0); (2) stage IB (T2a, N0) and stage IIA (T2b, N0); (3) stage IIA (T1ab-T2a, N1) and stage IIB (T3, N0; T2b N1); and (4) stage IIIA (T1-3, N2; T3, N1). The NCCN-recommended nonsurgical adjuvant therapy for group 1 is PORT; for group 2, PORT with or without chemotherapy; for groups 3 and 4, chemoradiation (sequential or concurrent) for R1 and concurrent chemoradiation for R2. 19 
Variables
Margin status was evaluated as negative (R0) or positive (R1, R2, or positive not otherwise specified), and in subsequent analyses R1 and R2 were evaluated individually. Covariates (detailed in Table 1 and  Table E2 ) in the analysis included patient demographics (age, sex, race, insurance status, income, rural/urban residence, census region), and clinical characteristics (comorbidity score [0, 1, or !2], histology, tumor grade, tumor size, primary site, type of surgery), as well as institutional characteristics (facility type).
Statistical Analysis
Overall survival (OS) times were taken from the date of surgery until the date of death or last follow-up. Survival analyses were conducted to compare the 4 postoperative treatment modalities within each of the 4 stage groups. OS was estimated using the Kaplan-Meier method and postoperative treatment groups were compared using the log-rank test.
OS comparisons also were evaluated using univariate and multiple variable Cox proportional hazards models to adjust for covariates. Model-based hazard ratio estimates are reported with 95% confidence intervals. For each model, we present unadjusted hazard ratios and hazard ratios adjusted for demographic, clinical, surgical, and institutional characteristics. The proportional hazards assumption was evaluated graphically, using log(Àlog) survival plots by treatment group. We used ''no adjuvant treatment'' as the reference adjuvant therapy option, because there is no clinical trial evidence to support adjuvant therapy after 
Sensitivity Analyses
We conducted multiple sensitivity analyses to address specific details of the analysis. First, the specific type of positive resection (R1 or R2) was unknown for some patients who were margin-positive. We evaluated the sensitivity of our results to margin-positivity of unknown type by conducting multiple analyses in which we grouped them as R1, R2, and eliminated them.
Additional sensitivity analyses were conducted to evaluate if departures from proportional hazards or the large number of covariates adjusted for in each model could affect the observed results from primary analysis. In these analyses, propensity scoreeadjusted models were used to control for demographic, clinical, surgical, and institutional characteristics with a propensity score, which was entered into the model as a covariate. 23 Finally, we evaluated the potential impact of departures from the proportional hazards assumption by reevaluating the multiple variable Cox models after eliminating any exposure groups where the assumption was questionable.
RESULTS
A total of 82,440 patients were eligible: 3461 (4%) with incomplete resection, the primary analysis group of interest (Figure 1 ), and 78,979 (96%) with R0 resection ( Figure E1 ), used to validate our analytic approach. The demographic and clinical characteristics of these patients, stratified by NCCN stage group ( (10) and E4, Figure 2 , A). This result trended toward statistical significance in the fully adjusted model (adjusted hazard ratio [aHR] 1.7, P ¼ .0551, Table 3 ). Similarly, for patients with stage IB/IIA, the 5-year OS was 47% with no treatment, and 25% with PORT (P ¼ .0251; aHR 1.28, P ¼ .12) (Table 3, Figure 2 , B). We found no significant association between chemotherapy and survival in patients with stage IA with positive margins; however, survival was significantly higher in persons with stages IB/IIA who received postoperative chemotherapy compared with no treatment (5-year OS: 62% vs 47%, P ¼ .0065, Table 3, Figure 2 , B). These results remained statistically significant in fully adjusted models (aHR 0.58, P ¼ .0040, Table 3 ). Sensitivity analysis using propensity scoreeadjusted models (Table E5 ), those that did not consider treatment groups in which the proportional hazards assumption may be violated (Table E6) , and those including only anatomic resections (Table E7) provided consistent results. Survival with chemoradiation was not significantly different from no adjuvant treatment in group 1 or 2 patients (Table 3) . Analysis restricted to patients with anatomic resections provided similar results (Table E7) .
Late-Stage Patients With Incomplete Resection: NCCN Groups 3 and 4
In margin-positive NCCN group 3, patients with stage IIA (T1ab-T2a, N1) or stage IIB (T3, N0; T2b N1), those who received radiation had a similar survival experience to those who received no treatment (5-year OS: 26% vs 27%, P ¼ .59, Figure 2 , C, Table 3 ). Recipients of chemotherapy or chemoradiation had superior survival (P <.0010, Table 3 , Figure 2 , C). Results were similar in fully adjusted models, where the chemotherapy group had 0.72 times the hazard of death compared with no treatment (P ¼ .0041), and the chemoradiation group had 0.74 times the hazard of death (P ¼ .0083).
Subsequent analysis found no substantial differences in survival in the chemoradiation group based on the order in which therapies were administered (Table E8) . When evaluated separately, patients receiving chemotherapy first and then radiation had 37% 5-year OS compared with 36% for patients receiving radiation first and then chemotherapy and 38% for those receiving both concurrently (Table E8) .
Consistent with NCCN guidelines, margin-positive patients with stage IIA or stage IIB were further delineated (7) 66 (5) 44 (7) 14 (3) 103 (11 (2) 35 (2) 15 (2) 8 (2) 15 (2) Black 342 (10) 147 (10) 67 (10) 34 (8) 94 (10) Other 88 (3) 29 (2) 18 (3) 17 (4) 24 (2) Missing 305 (9) 108 (8) 70 (11) 38 (9) 89 (9) Insurance Uninsured 87 (3) 37 (3) 14 (2) 9 (2) 27 (3) <.0001 Medicaid 176 (5) 69 (5) 23 (4) 23 (5) 61 (6) Younger Medicare 219 (6) 77 (5) 44 (7) 16 (4) 82 (9 based on the specific type of incomplete resection, R1, R2, or unknown (margin-positive, but type not specified). Although potentially limited by smaller sample sizes, results were largely consistent with those observed for all margin-positive patients combined (Table E9) . In margin-positive NCCN group 4, patients with stage IIIA (T1-3, N2; T3, N1), 5-year OS was similar between patients who received PORT (10%) and no treatment (12%, P ¼ .52, Figure 2, D) ; however, compared with no treatment, patients with chemotherapy alone had higher 5-year OS (21% vs 12%, P ¼ .0048), as did those with chemoradiation (25%, P <.0001). Fully adjusted models confirmed these findings (Table 3) . Specifically, the patients had a lower hazard of death in both the chemotherapy group (aHR 0.77, P ¼ .0466) and the chemoradiation group (aHR 0.63, P < .0001), compared with no treatment. Analyses restricted to patients with anatomic resection provided similar results (Table E7) .
Analysis of margin-positive patients with stage IIIA, after further stratification into R1 or R2 subsets, yielded similar results to the combined cohort (Table E9 ). Similar to group 3 patients, we found no meaningful difference in survival in patients with stage IIIA based on the order that chemoradiation was received (Table E8) .
Validation Analysis With Margin-Negative Resections
We applied the same analysis to the R0 resection cohort in a parallel analysis. Five-year OS, unadjusted proportional hazards models, and adjusted proportional hazards models in this cohort are presented in Table 4 , Figure E2 , and (4) 45 (3) 22 (3) 16 (4) 41 (4) C349-lung not otherwise specified 65 (2) 32 (2) 12 (2) 3 (1) 18 (2) T category T1 676 (20) 368 (26) 82 (13) 89 (20) 137 (14 (Table E11 ). The pattern of adjuvant therapy benefit in our analysis matched up with the evidence-based NCCN guidelines for R0 resection (Table 5) .
Comparison With NCCN Recommendations
Results from margin-positive and margin-negative analyses by stage groups are summarized qualitatively in Table 5 , and are compared with the current NCCN recommendations.
DISCUSSION
We compared OS between adjuvant therapy modalities in patients with completely and incompletely resected NSCLC, to determine if current NCCN recommendations are supported by a robust nationally representative dataset. Our primary interest was in the patients with incomplete resection, but we used the R0 cohort to validate our methodology, and the suitability of the NCDB for this purpose. This analysis consistently corroborated NCCN guidelines backed by high-level clinical trial evidence, but did not support current recommendations in several scenarios after incomplete resection, where the available evidence is sparse.
In patients with completely resected stage IA NSCLC, RCTs have shown no benefit from adjuvant therapy. 4, 6 In stage IB-IIB, RCTs and a pooled analysis including the 5 largest studies, have shown an increase in overall and relapse-free survival with postoperative cisplatin-based chemotherapy compared with observation. [4] [5] [6] 11 Our analysis of the R0 cohort is consistent with this evidence. Specifically, patients with completely resected stage IB-IIA NSCLC who received chemotherapy had results superior to all other treatment groups. In patients with completely resected stage IIIA NSCLC, current evidence supports chemotherapy for those with N0 or N1, and chemotherapy or chemoradiation for those with N2, which is the current NCCN recommendation. 19 The R0 cohort analysis supports the use of chemotherapy in patients with N0 and N1, and chemotherapy with or without radiation in patients with N2.
Incomplete resections occur relatively infrequently, and adjuvant therapy trials specifically exclude these patients. [4] [5] [6] [7] 10, 11, 24 Therefore, there is no definitive evidence on the best choice of postoperative therapy in this situation. [16] [17] [18] NCCN guidelines currently recommend PORT for group 1 (stage IA), PORT with or without chemotherapy for group 2 (stage IB and IIA), and chemoradiation for groups 3 (stage IIA with N1 and IIB) and 4 (T3N1 and T1-3,N2). 19 Our analysis supports observation for group 1, chemotherapy only for group 2, chemotherapy with or without radiation for group 3, and chemoradiation therapy for group 4. This analysis supports the NCCN recommendations for groups 3 and 4, but suggests that the current recommendations may be harmful to patients in groups 1 and 2. It also does not support the use of PORT alone in any subset.
Recent publications using the NCDB have provided conflicting results on the value of PORT after incomplete resection. Hancock and colleagues 18 found that chemotherapy or chemotherapy plus PORT provided superior 18 Both studies found that early-stage patients receiving PORT alone had shorter survival. However, we found the best survival for early-stage (NCCN group 2) patients was with chemotherapy alone compared with the findings of Hancock and colleagues, 18 who found that chemotherapy with or without PORT both showed similar survival that was superior to no adjuvant treatment or PORT alone for the undilineated group of patients with stage II and III.
The report by Wang and colleagues, 25 supporting the use of PORT in patients with stage II-III with incomplete resection, differed from our work by evaluating only patients with an optimal PORT experience. Specifically, Wang and colleagues 25 excluded all patients who died within 120 days of surgery, and included only patients who completed optimal-dose radiation. A less optimal classification of PORT use is more pragmatic and provides better information for treatment of patients, whose ability to receive a full treatment regimen of PORT cannot be known at the time of treatment decision. Patients who died as a result of acute radiation complications would have been excluded from their analysis. Another difference is that they treated chemotherapy as a confounding variable rather than a separate treatment option as we, and Hancock and colleagues, 18 have done. Our PORT analysis group included all persons who survived 60 days after surgery and received treatment with PORT within 6 months of surgery. Patients who discontinued PORT or who received PORT at a less-thanoptimal dose were included to adhere to the intention-totreat principle and avoid potential selection bias. Because treatment with PORT alone may be carried out differently from PORT with chemotherapy, we considered these 2 treatment options separately to better represent clinical practice and to avoid the potential for residual confounding by controlling for chemotherapy use exclusively through statistical modeling.
This retrospective study has several limitations. We have expressly excluded the primary recommendation of re-resection for non-R0 resections because of the relatively small number of such patients in the database. Ideally, PORT is preferably commenced within 60 days. We used a 6-month eligibility window, as others have done in these types of analyses, to reflect the practical reality that some patients start adjuvant therapy late. 18, 25 The median time to onset of PORT alone was 52 days, and 75% of patients initiated therapy within 74 days. This suggests that PORT was used adjuvantly, and not for salvage therapy after disease progression. However, (Table E9) NCDB, National Cancer Database; NCCN, National Comprehensive Cancer Network; Chemo, chemotherapy; RT, radiation therapy; Chemo þ RT, combined-modality chemotherapy and radiation therapy administered sequentially.
it is impossible to verify the clinical circumstances around any of the treatments. The NCDB covers 70% of all lung cancer cases in the United States, drawing from a diverse group of hospitals; however, results may not apply directly to substantially different institutions. Although the NCDB is thorough, incomplete and inaccurate data are still potential problems. Although we addressed this limitation for critical variables by validating our results with sensitivity analyses, unequal assignment of postoperative treatment modalities may have affected our results and the sample size of some analysis subsets may be too small for meaningful statistical inference. Outside a well-executed RCT, this remains a potential explanation for differences observed in all studies of this question. We have addressed this limitation as well as possible, with extensive adjustment by statistical analysis.
The lack of observed benefit from PORT or chemoradiation in early-stage patients after incomplete resection parallels the current evidence in completely resected patients; the impact of radiation therapy in reducing the increased cancer-related mortality risk after incomplete resection does not seem to overcome the excessive treatment-related mortality risk of PORT. 26 Chemotherapy appears to be valuable to some degree across stage groups; patients with mediastinal nodal metastasis seem to benefit from chemotherapy or combined-modality chemoradiation.
Well-conducted retrospective evaluations can lead to conflicting conclusions based on selection criteria for assigning treatment groups after the fact. An inherent imbalance between treatment groups before treatment initiation is likely when treatment is selected based on physician decision after individual patient assessment. Statistical adjustment is unlikely to completely eliminate such confounding-by-indication.
This study provides the most comprehensive evaluation of NCCN guidelines for postoperative therapy to date. Results are largely consistent with high-level evidence available after complete surgical resection. In patients with incomplete resection, in whom the available evidence is far less, these data did not support the use of PORT in early-stage patients. All available evidence in incompletely resected patients is lower-level, and results are discrepant. Only RCTs can definitively determine the best adjuvant therapy for incompletely resected NSCLC.
Such a trial will be challenging to execute because of the relatively low incidence of incomplete resections, and the practical reality that incomplete resections are least frequent in the types of institutions that typically conduct clinical trials. 16 However, infrastructure such as the National Cancer Institute's Community Oncology Research Program can be harnessed to support such a trial. The possibility of patient harm in the existing evidence void should stimulate the political will to resolve this question.
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